Orthotopic liver transplantation and what to do during follow-up: Recommendations for the practitioner

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 6, Issue 1, 2009, Pages 23-36

  Benten, Daniel ^a   Staufer, Katharina ^a   Sterneck, Martina ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA GLUCOSIDASE INHIBITOR; AMLODIPINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; COLECALCIFEROL; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FLUINDOSTATIN; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PEGINTERFERON; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; REPAGLINIDE; RIBAVIRIN; TACROLIMUS; UNINDEXED DRUG;

ACNE; AKINETIC MUTISM; ALOPECIA; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CONVULSION; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DISEASE SURVEILLANCE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; GASTRITIS; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HEPATIC ARTERY; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOMA; MEDICAL PRACTICE; MOUTH ULCER; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; TREMOR; WOUND HEALING IMPAIRMENT;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIANS, FAMILY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE;

EID: 58149528032     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1312     Document Type: Review

References (110)

1. Roberts MS et al. (2004) Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. Liver Transpl 10: 886-897
2. Pruthi J et al. (2001) Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 7: 811-815
3. Moreno R and Berenguer M (2006) Post-liver transplantation medical complications. Ann Hepatol 5: 77-85
4. Muñoz SJ and Elgenaidi H (2005) Cardiovascular risk factors after liver transplantation. Liver Transpl 11 (suppl 2): S52-S56
5. Rosen HR (2008) Transplantation immunology: What the clinician needs to know for immunotherapy. Gastroenterology 134: 1789-1801
6. Meier-Kriesche HU et al. (2006) Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131
7. Liu LU and Schiano TD (2007) Long-term care of the liver transplant recipient. Clin Liver Dis 11: 397-416
8. Ojo AO et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940
9. Ojo AO (2007) Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 27: 498-507
10. Cicinnati VR et al. (2007) Clinical trial: Switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 26: 1195-1208
11. Schlitt HJ et al. (2001) Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 357: 587-591
12. ClinicalTrials.gov (online September 2006) Study comparing sirolimus with cyclosporine in a calcineurin inhibitor (CNI)-free regimen in kidney transplant recipients [http://clinicaltrials.gov/ct2/show/ NCT00137345?cntry1=ME%3ACY&rank=4]
13. ClinicalTrials.gov (online June 2008) RESCUE study-everolimus in liver transplant recipients with renal insufficiency [http://www.clinicaltrials.gov/ct2/show/NCT00267189?term= 001H2401&rank=1]
14. ClinicalTrials.gov (online July 2008) Preservation of renal function in liver transplant recipients with certican therapy [http://www.clinicaltrials.gov/ct2/show/NCT00378014?term= 001HDE10&rank=1]
15. Sheiner PA et al. (2000) Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 69: 781-789
16. Stegall MD et al. (1997) Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 25 173-177
17. Lucey MR et al. (2005) A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 5: 1111-1119
18. Chobanian AV et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252
19. Mells G and Neuberger J (2007) Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 83: 1141-1150
20. Neal DA et al. (2004) Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 77: 748-750
21. Neal DA and Alexander GJ (2001) Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation? Liver Transpl 7: 1009-1014
22. Gazi IF et al. (2006) Statins and solid organ transplantation. Curr Pharm Des 12: 4771-4783
23. Neal DA et al. (2001) Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 7: 533-539
24. Imagawa DK et al. (1996) Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 62: 934-942
25. Taylor PJ et al. (2004) Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 38: 205-208
26. Heisel O et al. (2004) New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 4: 583-595
27. Moon JI et al. (2006) Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 82: 1625-1628
28. Dumortier J et al. (2006) Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 12: 659-664
29. Wilkinson A et al. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19: 291-298
30. Villanueva G and Baldwin D (2005) Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80: 1402-1405
31. Guichelaar MM et al. (2006) Bone mineral density before and after OLT: Long-term follow-up and predictive factors. Liver Transpl 12: 1390-1402
32. Stein E et al. (2007) Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 36: 937-963
33. Crawford BA et al. (2006) Zoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 144: 239-248
34. Ninkovic M et al. (2000) Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12: 931-935
35. Compston JE (2003) Osteoporosis after liver transplantation. Liver Transp 9: 321-330
36. Schneider V et al. (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 164: 881-889
37. Fishman JA and Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338: 1741-1751
38. Sharma S et al. (2008) Biliary strictures following liver transplantation: Past, present and preventive strategies. Liver Transpl 14: 759-769
39. Avery R and Michaels M (2008) Update on immunizations in solid organ transplant recipients: What clinicians need to know. Am J Transplant 8: 9-14
40. Khan S et al. (2006) Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 10: 78-82
41. Herrero JI et al. (2005) De novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. Liver Transpl 11: 89-97
42. Oo YH et al. (2005) Incidence of cancers following orthotopic liver transplantation in a single center: Comparison with national cancer incidence rates for England and Wales. Transplantation 80: 759-764
43. Penn I (1996) Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 2: 52-59
44. Snow AL and Martinez OM (2007) Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 7: 271-277
45. Opelz G and Dohler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4: 222-230
46. Aucejo F et al. (2006) Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol 44: 19-23
47. Bakker NA et al. (2007) Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int 20: 207-218
48. Cullis B et al. (2006) Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47: E67-e72
49. Majewski M et al. (2003) Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75: 1710-1717
50. Frey NV and Tsai DE (2007) The management of posttransplant lymphoproliferative disorder. Med Oncol 24: 125-136
51. American Cancer Society (online 5 March 2008) American Cancer Society guidelines for the early detection of cancer. [http://www.cancer.org/ docroot/ped/content/ped_2_3x_acs_cancer_detection_guidelines_36.asp]
52. Duvoux C et al. (1999) Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 67: 418-421
53. Presser SJ et al. (2007) De novo esophageal neoplasia after liver transplantation. Liver Transpl 13: 443-450
54. Knight SR et al. (2007) Role of transplantation in the management of hepatic malignancy. Br J Surg 94: 1319-1330
55. Mazzaferro V et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699
56. Yao FY et al. (2002) Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8: 765-774
57. Andrassy J et al. (2005) mTOR inhibition and its effect on cancer in transplantation. Transplantation 80 (suppl 1): S171-S174
58. Benten D et al. (2008) Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 14: 789-798
59. Gane EJ et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334: 815-820
60. Samuel D et al. (2006) Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 45: 127-143
61. Berenguer M et al. (2008) Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 8: 679-687
62. Terrault N et al. (2005) Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpl 11: 716-732
63. Sherman M et al. (2007) Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 21 (suppl C): S5-S24
64. Seehofer D and Berg T (2005) Prevention of hepatitis B recurrence after liver transplantation. Transplantation 80 (suppl 1): S120-S124
65. Roche B and Samuel D (2005) Treatment of hepatitis B and C after liver transplantation. Part 1: Hepatitis B. Transpl Int 17: 746-758
66. Rosenau J et al. (2007) Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 13: 367-373
67. Starkel P et al. (2005) Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 11: 1228-1234
68. European Liver Transplant Registry [http://www.eltr.org]
69. Gautam M et al. (2006) Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl 12: 1813-1824
70. Luettig B et al. (1998) The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J Hepatol 28: 824-828
71. Schreibman I and Regev A (2006) Recurrent primary biliary cirrhosis after liver transplantation-the disease and its management. MedGenMed 8: 30
72. Liermann Garcia RF et al. (2001) Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 33: 22-27
73. Bjoro K et al. (2006) Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 26: 69-79
74. Demetris AJ (2006) Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 12: S68-S72
75. Cholongitas E et al. (2008) Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 14: 138-143
76. Schramm C et al. (2008) Long term outcome of patients transplanted for autoimmune hepatitis-analysis of the European liver transplant registry [abstract #102]. J Hepatol 48: S47
77. Gonzalez-Koch A et al. (2001) Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 7: 302-310
78. Ratziu V et al. (1999) Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. J Hepatol 30: 131-141
79. Molmenti EP et al. (2002) Incidence and recurrence of autoimmune/ alloimmune hepatitis in liver transplant recipients. Liver Transpl 8: 519-526
80. Duclos-Vallee JC et al. (2003) A 10 year follow up study of patients transplanted for autoimmune hepatitis: Histological recurrence precedes clinical and biochemical recurrence. Gut 52: 893-897
81. Kerkar N et al. (2005) Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 5: 1085-1089
82. Demetris A et al. (2000) Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection, an international panel. Hepatology 31: 792-799
83. Gaglio P and Brown R (2006) Post liver transplantation management and complications. In Zakim and Boyer's Hepatology: A Textbook of Liver Disease, edn 5, 961-974 (Eds Boyer TD et al.) Philadelphia: Saunders
84. Uemura T et al. (2008) Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 22 316-323
85. Kashyap R et al. (2001) Causes of retransplantation after primary liver transplantation in 4,000 consecutive patients: 2 to 19 years follow-up. Transplant Proc 33: 1486-1487
86. Neuberger J (1999) Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 5 (suppl 1): S30-S36
87. Pfitzmann R et al. (2008) Long-term results after liver transplantation. Transpl Int 21: 234-246
88. Yazumi S and Chiba T (2005) Biliary complications after a right-lobe living donor liver transplantation. J Gastroenterol 40: 861-865
89. Lee HW et al. (2007) Classification and prognosis of intrahepatic biliary stricture after liver transplantation. Liver Transpl 13 1736-1742
90. Fusai G et al. (2006) Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. Liver Transpl 12: 1626-1633
91. Roumilhac D et al. (2003) Long-term results of percutaneous management for anastomotic biliary stricture after orthotopic liver transplantation. Liver Transpl 9: 394-400
92. Buis CI et al. (2006) Causes and consequences of ischemic-type biliary lesions after liver transplantation. J Hepatobiliary Pancreat Surg 13: 517-524
93. Millonig G et al. (2006) Bactobilia after liver transplantation: frequency and antibiotic susceptibility. Liver Transpl 12: 747-753
94. Paumgartner G and Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531
95. Silva MA et al. (2006) Hepatic artery thrombosis following orthotopic liver transplantation: A 10-year experience from a single centre in the United Kingdom. Liver Transpl 12: 146-151
96. Valente JF et al. (1996) Late hepatic artery thrombosis in liver allograft recipients is associated with intrahepatic biliary necrosis. Transplantation 61: 61-65
97. Bhattacharjya S et al. (2001) Delayed hepatic artery thrombosis in adult orthotopic liver transplantation- a 12-year experience. Transplantation 71: 1592-1596
98. Rabkin JM et al. (2001) Late mortality after orthotopic liver transplantation. Am J Surg 181: 475-479
99. Vignali C et al. (2004) Role of interventional radiology in the management of vascular complications after liver transplantation. Transplant Proc 36: 552-554
100. Abbasoglu O et al. (1997) Hepatic artery stenosis after liver transplantation - incidence, presentation, treatment, and long term outcome. Transplantation 63: 250-255
101. Dew MA et al. (1997) Does transplantation produce quality of life benefits? A quantitative analysis of the literature. Transplantation 64: 1261-1273
102. Tome S et al. (2008) Quality of life after liver transplantation: a systematic review. J Hepatol 48: 567-577
103. Pinson CW et al. (2000) Health-related quality of life after different types of solid organ transplantation. Ann Surg 232 597-607
104. Rothenhausler HB et al. (2002) Psychiatric and psychosocial outcome of orthotopic liver transplantation. Psychother Psychosom 71: 285-297
105. Singh N et al. (1999) Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 67: 69-72
106. Cuadrado A et al. (2005) Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 11: 420-426
107. Dew MA et al. (2008) Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 14: 159-172
108. Adams PC et al. (1995) Employment after liver transplantation. Hepatology 21: 140-144
109. Kirchner GI et al. (2006) Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 12: 1268-1277
110. Newton SE (1999) Recidivism and return to work posttransplant: recipients with substance abuse histories. J Subst Abuse Treat 17: 103-108